Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Potential Target Antigens and Critical Aspects for a Universal Influenza Vaccine

Overview

Journal Cold Spring Harb Perspect Biol

Specialties Biology
Molecular Biology

Date 2017 Jul 1

PMID 28663209

Citations 63

Authors

Florian Krammer

Adolfo Garcia-Sastre

Peter Palese

Affiliations

Soon will be listed here.

Abstract

Influenza viruses cause seasonal epidemics as well as pandemics and are a significant concern for human health. Current influenza virus vaccines show efficacy when they are antigenically well matched to circulating strains. Seasonal influenza viruses undergo antigenic drift at a high rate and, therefore, current vaccines have to be reformulated and readministered on an annual basis. Mismatches between vaccine strains and circulating strains frequently occur, significantly decreasing vaccine efficacy. In addition, current seasonal influenza virus vaccines have limited efficacy against newly emerging pandemic viruses. A universal influenza virus vaccine that induces long-term protection against all influenza virus strains would abolish the need for annual readministration of seasonal influenza virus vaccines and would significantly enhance our pandemic preparedness. Here we discuss the characteristics of universal influenza virus vaccines, their potential target antigens, and critical aspects to consider on the path to successfully developing such vaccines.

Citing Articles

Structural characterization of influenza group 1 chimeric hemagglutinins as broad vaccine immunogens.

Nguyen Y, Zhu X, Han J, Rodriguez A, Sun W, Yu W Proc Natl Acad Sci U S A. 2025; 122(7):e2416628122.

PMID: 39937865 PMC: 11848309. DOI: 10.1073/pnas.2416628122.

Virology-The next fifty years.

Holmes E, Krammer F, Goodrum F Cell. 2024; 187(19):5128-5145.

PMID: 39303682 PMC: 11467463. DOI: 10.1016/j.cell.2024.07.025.

Sequential immunization with chimeric hemagglutinin ΔNS1 attenuated influenza vaccines induces broad humoral and cellular immunity.

Rathnasinghe R, Chang L, Pearl R, Jangra S, Aspelund A, Hoag A NPJ Vaccines. 2024; 9(1):169.

PMID: 39300090 PMC: 11413010. DOI: 10.1038/s41541-024-00952-7.

Double-layered protein nanoparticles conjugated with truncated flagellin induce improved mucosal and systemic immune responses in mice.

Kim J, Zhu W, Dong C, Wei L, Ma Y, Denning T Nanoscale Horiz. 2024; 9(11):2016-2030.

PMID: 39240547 PMC: 11493517. DOI: 10.1039/d4nh00287c.

Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine.

Cowling B, Okoli G Drugs. 2024; 84(9):1013-1023.

PMID: 39167316 PMC: 11438668. DOI: 10.1007/s40265-024-02083-8.

References

de Jong J, Beyer W, Palache A, Rimmelzwaan G, Osterhaus A . Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol. 2000; 61(1):94-9. View

Kissling E, Nunes B, Robertson C, Valenciano M, Reuss A, Larrauri A . I-MOVE multicentre case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination?. Euro Surveill. 2016; 21(16). DOI: 10.2807/1560-7917.ES.2016.21.16.30201. View

Xie H, Wan X, Ye Z, Plant E, Zhao Y, Xu Y . H3N2 Mismatch of 2014-15 Northern Hemisphere Influenza Vaccines and Head-to-head Comparison between Human and Ferret Antisera derived Antigenic Maps. Sci Rep. 2015; 5:15279. PMC: 4607887. DOI: 10.1038/srep15279. View

Vanderven H, Ana-Sosa-Batiz F, Jegaskanda S, Rockman S, Laurie K, Barr I . What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins. EBioMedicine. 2016; 8:277-290. PMC: 4919476. DOI: 10.1016/j.ebiom.2016.04.029. View

Castilla J, Martinez-Baz I, Martinez-Artola V, Reina G, Pozo F, Garcia Cenoz M . Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill. 2013; 18(5). DOI: 10.2807/ese.18.05.20388-en. View

Scorza F, Tsvetnitsky V, Donnelly J . Universal influenza vaccines: Shifting to better vaccines. Vaccine. 2016; 34(26):2926-2933. PMC: 4899887. DOI: 10.1016/j.vaccine.2016.03.085. View

Henry Dunand C, Leon P, Huang M, Choi A, Chromikova V, Ho I . Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection. Cell Host Microbe. 2016; 19(6):800-13. PMC: 4901526. DOI: 10.1016/j.chom.2016.05.014. View

Nguyen X, Saoudi A, Liblau R . Vaccine-associated inflammatory diseases of the central nervous system: from signals to causation. Curr Opin Neurol. 2016; 29(3):362-71. DOI: 10.1097/WCO.0000000000000318. View

Luke C, Subbarao K . Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms. Expert Rev Vaccines. 2014; 13(7):873-83. DOI: 10.1586/14760584.2014.922416. View

10.

Chai N, Swem L, Reichelt M, Chen-Harris H, Luis E, Park S . Two Escape Mechanisms of Influenza A Virus to a Broadly Neutralizing Stalk-Binding Antibody. PLoS Pathog. 2016; 12(6):e1005702. PMC: 4924800. DOI: 10.1371/journal.ppat.1005702. View

11.

Wohlbold T, Krammer F . In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen. Viruses. 2014; 6(6):2465-94. PMC: 4074938. DOI: 10.3390/v6062465. View

12.

Grant E, Quinones-Parra S, Clemens E, Kedzierska K . Human influenza viruses and CD8(+) T cell responses. Curr Opin Virol. 2016; 16:132-142. DOI: 10.1016/j.coviro.2016.01.016. View

13.

Duan S, Thomas P . Balancing Immune Protection and Immune Pathology by CD8(+) T-Cell Responses to Influenza Infection. Front Immunol. 2016; 7:25. PMC: 4742794. DOI: 10.3389/fimmu.2016.00025. View

14.

Flannery B, Clippard J, Zimmerman R, Nowalk M, Jackson M, Jackson L . Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015. MMWR Morb Mortal Wkly Rep. 2015; 64(1):10-5. PMC: 4584793. View

15.

Tricco A, Chit A, Soobiah C, Hallett D, Meier G, Chen M . Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med. 2013; 11:153. PMC: 3706345. DOI: 10.1186/1741-7015-11-153. View

16.

Schotsaert M, De Filette M, Fiers W, Saelens X . Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines. 2009; 8(4):499-508. PMC: 2706389. DOI: 10.1586/erv.09.6. View

17.

Beare A, Webster R . Replication of avian influenza viruses in humans. Arch Virol. 1991; 119(1-2):37-42. DOI: 10.1007/BF01314321. View

18.

Lowen A, Steel J, Mubareka S, Carnero E, Garcia-Sastre A, Palese P . Blocking interhost transmission of influenza virus by vaccination in the guinea pig model. J Virol. 2009; 83(7):2803-18. PMC: 2655561. DOI: 10.1128/JVI.02424-08. View

19.

Molinari N, Ortega-Sanchez I, Messonnier M, Thompson W, Wortley P, Weintraub E . The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007; 25(27):5086-96. DOI: 10.1016/j.vaccine.2007.03.046. View

20.

Klein S, Marriott I, Fish E . Sex-based differences in immune function and responses to vaccination. Trans R Soc Trop Med Hyg. 2015; 109(1):9-15. PMC: 4447843. DOI: 10.1093/trstmh/tru167. View